Rotavirus Infections - Pipeline Review, H1 2018

  • ID: 4518483
  • Report
  • 51 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Curevac AG
  • GlaxoSmithKline Plc
  • Medicago Inc
  • UMN Pharma Inc
  • MORE
Rotavirus Infections - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2018, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights:

This latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II, Discovery and Unknown stages comprises 4, 1 and 1 molecules, respectively.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biological E Ltd
  • Curevac AG
  • GlaxoSmithKline Plc
  • Medicago Inc
  • UMN Pharma Inc
  • MORE
Introduction

Report Coverage

Rotavirus Infections - Overview

Rotavirus Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Rotavirus Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rotavirus Infections - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Bharat Biotech International Ltd

Biological E Ltd

Curevac AG

GlaxoSmithKline Plc

Medicago Inc

Serum Institute of India Ltd

UMN Pharma Inc

Wuhan Institute of Biological Products Co Ltd

Rotavirus Infections - Drug Profiles

(rotavirus (virus like particle) + typhiod) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavac-5C - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus (virus like particle) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G8, G9] (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus [serotypes G1, G2, G3, G4, P1] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rotavirus vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-3BB - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RV-625 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UMN-2001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rotavirus Infections - Dormant Projects

Rotavirus Infections - Product Development Milestones

Featured News & Press Releases

Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification

Sep 26, 2017: Serum Institute's vaccine demonstrates significant efficacy against severe rotavirus

Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus

Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate

Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus

Apr 26, 2012: GSK’s Rotarix to Be Introduced in Ghana

Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan

May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rotavirus Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2018

Rotavirus Infections - Pipeline by Bharat Biotech International Ltd, H1 2018

Rotavirus Infections - Pipeline by Biological E Ltd, H1 2018

Rotavirus Infections - Pipeline by Curevac AG, H1 2018

Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2018

Rotavirus Infections - Pipeline by Medicago Inc, H1 2018

Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2018

Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2018

Rotavirus Infections - Pipeline by Wuhan Institute of Biological Products Co Ltd, H1 2018

Rotavirus Infections - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Rotavirus Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Curevac AG
  • GlaxoSmithKline Plc
  • Medicago Inc
  • Serum Institute of India Ltd
  • UMN Pharma Inc
  • Wuhan Institute of Biological Products Co Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll